BiomX (PHGE) Current Deferred Revenue (2021 - 2024)

BiomX (PHGE) posted Current Deferred Revenue of $2.0 million for Q3 2024, little changed sequentially from $2.0 million in Q2 2024.

BiomX (PHGE) Current Deferred Revenue (2021 - 2024) Analysis & Trends

BiomX has reported Current Deferred Revenue for 4 years, with the latest figure at $2.0 million in Q3 2024.

Quarterly Current Deferred Revenue changed N/A year-over-year to $2.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.0 million (changed N/A YoY) and the FY2023 annual result came in at $28000.0, changed N/A from the prior year.
Current Deferred Revenue was little changed at $2.0 million in Q3 2024 per PHGE's latest filing, from $2.0 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $2.0 million in Q4 2021 and troughed at $28000.0 in Q4 2023.
A 4-year average of $1.7 million and a median of $2.0 million in 2021 frame the typical range for Current Deferred Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	BiomX	361,408.40	-806,591.60	-

Download Data